All Oncology News

Imlunestrant joins the treatment arsenal for ESR1-mutated metastatic breast cancer, T-DXd doublet gets priority review in HER2+ breast cancer, and more.

OncLive social media polls reveal which lung cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Ramez N. Eskander, MD, discusses prior data supporting the ongoing investigation of sacituzumab govitecan as monotherapy in endometrial cancer.

OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.

Five new faculty members join network; three at St. Joseph’s Health in Syracuse as it launches new services.

The NCCN has issued a category 2A recommendation for revumenib in relapsed/refractory acute myeloid leukemia harboring an NPM1 mutation.

Stenoparib monotherapy generated long-term clinical benefit in patients with platinum-resistant and -refractory advanced ovarian cancer.

Lyudmila A. Bazhenova, MD, discusses the FDA approval of sunvozertinib (Zegfrovy) in patients with EGFR exon 20–mutant non–small cell lung cancer.

Jennifer A. Woyach, MD, discusses the potential of pirtobrutinib as a second-line option for patients with CLL.

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

The FDA has removed the REMS program for vandetanib for the treatment of patients with medullary thyroid cancer.

Atebimetinib plus modified gemcitabine/nab-paclitaxel continued to elicit high OS rates in patients with treatment-naive pancreatic cancer.

The FDA approved imlunestrant for ER-positive, HER2-negative advanced or metastatic ESR1-mutated breast cancer following endocrine therapy.

Mitazalimab plus mFOLFIRINOX demonstrated encouraging survival outcomes in previously untreated metastatic pancreatic cancer.

Through a new agreement, nurse scientists from Dana-Farber will become Northeastern faculty members, bringing oncology nursing science into the classroom.

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

Utidelone injection has received orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.

A United Kingdom Conformity Assessed marking was granted to the Avantect Multi-Cancer Detection Test and Avantect Ovarian Cancer Test.

An indirect comparison of SEQUOIA and CLL14 shows zanubrutinib improved PFS over venetoclax/obinutuzumab in treatment-naive CLL after baseline adjustment.

Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.

Real-world data highlighted differences in the timing and severity of belzutifan-related toxicities in VHL-associated tumors and sporadic RCC.

Dana M. Chase, MD, discusses the effect of the frontline dostarlimab plus chemotherapy on the recurrent endometrial cancer landscape.

The SCOPE score was predictive of response, toxicity, and survival outcomes in patients with relapsed/refractory myeloma receiving BCMA CAR T-cell therapy.

Alnodesertib has received fast track designation from the FDA for patients with ATM-negative metastatic colorectal cancer.

Frontline T-DXd plus pertuzumab is under FDA priority review for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.

The collaboration blends LSU Health New Orleans’s robust research capabilities with IIT Madras’ technology innovation to drive global health impact.

Paul Gellhaus, MD, spotlights key technological advancements and the need for consensus on PSA screening guidance during prostate cancer awareness month.

Theresa Medina, MD, discusses 5-year C-144-01 results with lifileucel in advanced melanoma.

A panel of hematologic cancer experts discusses data on GVHD management from the 2025 SOHO Annual Meeting.

Brian Slomovitz, MD, spotlights key advancements in disease management and prevention during Gynecologic Cancer Awareness Month.